Full-Time
Regional Service Manager
Updated on 9/3/2026
Thermo Fisher Scientific
10,001+ employees
Lab supplies, instruments, and biopharma services
No salary listed
Mumbai, Maharashtra, India
Hybrid
Hybrid role; occasional on-site days in Mumbai.
Bachelor's
 Field Service (1) |
|---|
Get referred to Thermo Fisher Scientific
See people who can refer or advise you
- Team Leadership: Manage and proactively lead the regional service team through all stages of the client lifecycle—from administration and planning to execution and completion.
- Revenue Generation: Drive regional profitability by achieving or exceeding targets for service contracts (AMCs/CMCs) and spare parts sales.
- Operational Excellence: Monitor team KPIs, ensuring adherence to budgets, timelines, and quality standards.
- Customer Allegiance: Improve Customer Allegiance Scores (CAS) by maintaining strong relationships with existing clients and identifying new business opportunities.
- Compliance: Ensure all team activities align with corporate policies, HR compliance, and safety standards.
- Mentorship: Lead, coach, and develop FSEs to upgrade their technical skills and prepare them for future leadership roles.
- Succession Planning: Identify and groom a successor through a structured development plan in line with organizational growth.
- Culture: Foster a high-performing team environment built on empathy, ownership, and accountability.
- Domain Expertise: Strong knowledge of process applications specifically within the Cement, Steel, and Process industries.
- Troubleshooting: Apply advanced logical and analytical diagnostic skills to perform Root Cause Analysis (RCA) and resolve complex instrument issues.
- Software Proficiency: Expert use of Service Management Software and the Microsoft Office suite.
- Influence Without Authority: Ability to lead cross-functional teams and drive results through persuasion and partnership.
- Conflict Management: Skilled at handling difficult customer situations and critical technical escalations with a "soft-spoken" yet firm professional demeanour.
- Strategic Thinking: Ability to balance immediate technical fixes with long-term business objectives.
- Education: Bachelor’s degree Electrical, Electronics, Instrumentation or Mechanical Engineering.
- Experience: 10+ years of total working experience.
- Minimum 5 years in Customer Service Management.
- 3+ years in a direct supervisory/leadership role managing technical teams.
- Technical Hands-on: Experience on Analytical instruments and Direct experience with XRF/OES/Process analyzers analytical instruments is additional advantage.
- Language: Proficiency in English; multilingual skills are a plus depending on the specific region.
- Manage a field service team to deliver installation, maintenance, repairs, and customer support for sophisticated analytical and scientific instruments.
- Provide installation, maintenance, repairs, and customer support while exhibiting technical leadership and people management.
- Develop and execute service strategies that grow revenue and enhance customer satisfaction in collaboration with sales, technical support, and other stakeholders.
- Help advance scientific service delivery by implementing effective solutions, optimizing team performance, and building strong customer relationships.
- Support continuous improvement initiatives while maintaining the highest standards of quality and safety.
- Collaborate with sales, technical support, and other stakeholders to develop and execute service strategies that grow revenue and enhance customer satisfaction.
Thermo Fisher Scientific supplies labs, hospitals, and biotech firms with a broad range of products and services, from basic lab consumables to advanced analytical instruments and outsourced drug development. Its offerings work by combining high-tech instruments for genomics, diagnostics, and research with consumables and a global distribution network to deliver end-to-end workflows that turn samples into data and insights. The company differentiates itself through its massive, diversified portfolio and its integrated end-to-end reach—from tools and reagents to support services—built on the legacy of Fisher Scientific’s distribution strength and Thermo Electron’s instrument innovation, backed by a history of strategic acquisitions. The goal is to be the dominant partner in science and healthcare by enabling researchers and clinicians to perform work more efficiently and at larger scale, spanning discovery, development, and manufacturing.
Company Size
10,001+
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
1956
Get referred to Thermo Fisher Scientific
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 10.5% to $11.99 billion, and EPS beat estimates.
- Thermo Fisher raised 2026 guidance to $47.4 billion-$48.1 billion on July 23.
- KAIST and UQ partnerships on August 26-27 expand autonomous labs and talent pipelines.
What critics are saying
- Thermo Fisher is selling microbiology for $1.075 billion, shrinking Specialty Diagnostics revenue in Q3 2026.
- Management flagged roughly $220 million of 2026 restructuring charges in Laboratory Products and Biopharma Services.
- Future acquisition antitrust scrutiny cripples Thermo Fisher’s post-2006 growth model.
What makes Thermo Fisher Scientific unique
- Thermo Fisher’s August 2026 Orbitrap Isora makes isotope-ratio mass spectrometry mainstream.
- EMPAD G2, launched August 27, 2026, deepens materials imaging through 4D STEM.
- Its scale spans reagents, instruments, diagnostics, and PPD services across every lab workflow.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Fertility Treatment Support
Family Planning Benefits
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Company News
Antibody data manipulation extends to thousands of images across 15 suppliers. After identifying antibody validation data manipulation in Thermo Fisher Scientific's catalogue in May, the science sleuths and researchers behind the finding have now uncovered doctored validation data on a much larger scale, with over 18,000 images relating to over 17,000 antibodies from at least 15 different supplier companies. Reese Richardson, Elisabeth Bik and Sholto David - who spotted the first doctored blot - have led the investigation. Community reports have also come in from across the world, with the annotated images continuing to be collated in an online repository. The team has traced some suspected image manipulation back over a decade ago. The team has uncovered various forms of image manipulation - this example from Abcam includes areas of background that have been duplicated The companies identified span major suppliers as well as more specialist firms, including MilliporeSigma, G-Biosciences, Proteogenix, Abcam and Origene. Western blots - which show how an antibody binds to a given protein - and other validation images have been identified as manipulated, calling into question not just transparency but antibody performance. This includes 'painting' of immunofluorescence images used to visualise the distribution or localisation in cells. I think that everybody should be demanding change. It's a massive insult from for-profit companies to the research community. Reese Richardson Image integrity expert Bik says Western blot manipulation is easier to uncover, but immunofluorescence manipulation takes more digging. With increasing use of artificial intelligence (AI), identifying doctored images is becoming more difficult. While she wasn't surprised to discover image manipulation from more companies, Bik says the extent is 'shocking' to see. 'I'm very worried about AI,' she adds. 'It may be already happening that images are AI-generated, and how will we detect that?' Until now, she suggests, there has been a level of trust and expectation of quality - given the high prices of antibody reagents. When experiments fail, or results are not as clean as expected, researchers tend to attribute that to their own errors, rather than ineffective reagents. Bik says the impact on research is unmeasurable but 'it must be millions or billions in wasted research funding'. It also raises ethical questions for researchers who use these antibodies as part of animal studies. Bik adds there must be 'some degree of regulation' introduced. Richardson says the contributions and support from scientists gives him hope for change: 'I think that everybody should be demanding change. It's an immense waste of [researchers'] time [and resources] that people have been buying antibodies based off fabricated data. It's a massive insult from for-profit companies to the research community. What we need now is transparency.' The teams have found hundreds of images in which protein binding bands appear to have been pasted onto the same background image. Some background patterns are present across images from multiple different companies Following the pattern Richardson explains that with image background patterns being replicated for antibodies across different companies, it's likely for many that 'no experiment took place'. He adds that many companies are buying antibodies from the same manufacturer, then selling them under their own brands at different prices (and with different quality guarantees) without clearly disclosing the source. However, some companies' validation data show 'unique styles' of image manipulation - like Proteogenix and Santa Cruz Biotechnology - with individual patterns reused extensively within their own antibody catalogues. This leads Richardson to suspect 'fudging the validation data' may be common practice across the industry. The companies with the largest number of doctored images are G-Biosciences and Thermo, each with more than 5000 images identified, and LSBio and Origene with more than 2000 images each. However, without running a complete audit of all the companies' catalogues, the full extent of the problem remains unclear. Thermo and Abcam have begun their own internal reviews. Thermo says it has so far found 'no evidence of impact to antibody performance' and is updating and replacing some Western blot images, as well as adding labelling to distinguish raw, unedited images from those that may have been 'edited, optimised or adjusted'. Tracing the changes Richardson explains that forensic image analysis tools can reveal metadata showing when images were opened in Photoshop and other editing software. With this, science sleuths tracked some of the alterations made over time. However, he is clear that this alone is 'not a smoking gun', since Photoshop can be used to make legitimate changes such as cropping and adding labels. The incriminating evidence, he says, is traces of multiple modifications that go beyond what would be required for simple labelling. Another example of repeated use of the same background pattern to create multiple images, this time all taken from Proteogenix's catalogue This includes some images first logged as far back as 2011: 'Many don't just preserve the first time an image was created and when it was last modified, but session data for every modification made along the way,' he explains. Taking the images that share one specific background pattern, for instance, the team can reconstruct an evolutionary tree from the original image, showing every time it was modified thereafter. Modifications have unique session identifiers but do not show how the image was altered. 'You can see if the first 20 session IDs match the whole 20 of a different image, so you can see where an image was branched off and manipulated from the same template,' he says. One example has up to 80 different session IDs, suggesting modification goes far beyond acceptable changes for presentation. I hope there will be some lawsuit, I'm not a fan of suing people in general but this is a big scandal Elisabeth Bik While the original data is needed for a clearer picture, the thousands of images identified so far represents the proportion uncovered after hours of work from the science sleuths - often alongside other work. Bik says there's little individual scientists can do, but companies should now be checking their supply chains, identifying fault and taking responsibility. However, she has 'little hope' change will come soon. 'I don't know how they'll rebuild trust. I hope there will be some lawsuit, I'm not a fan of suing people in general but this is a big scandal.' Few scientists will feel they have the time or means for such a lawsuit, however, and pressure to keep producing results means they are unlikely to boycott major antibody suppliers. She suggests that research funders like the US National Institutes of Health could potentially pursue lawsuits for wasted funding, but most likely, she suggests 'nothing will happen'. Richardson sees this as a 'cautionary tale' of the privatisation of essential research services in general and specifically the for-profit model of antibody production. Independent organisation YCharOS validating antibodies with gold standard protocols estimates these tests can cost up to $25,000 per reagent. He says this cost, combined with the lack of regulatory oversight, provides an incentive to either modify or fabricate validation data. He agrees with Bik that regulation is necessary. In the meantime, Richardson says researchers should run their own validation, since 'clearly, we cannot count on the industry to do it for us'. Frankie Macpherson is digital content assistant working with the wider Chemistry World team to help create and publish articles, social media content, podcasts and deliver events. View full profile
Thermo Fisher Launches Multiskan Ease Microplate Reader 2nd September 2026 We have hundreds of jobs available across the Healthcare industry, find your perfect one now. Receive the latest industry news, Tips and straight to your inbox.
Thermo Fisher Scientific has launched the Multiskan Ease Absorbance Microplate Reader, designed to simplify protein quantification, enzyme-linked immunosorbent assays, cell viability studies and microbial growth monitoring in laboratories. The device was developed for laboratories facing budget constraints, shared resources and workforce challenges that need a straightforward absorbance solution for routine biological assays. It supports applications including protein quantification, ELISAs, enzyme activity analysis, endotoxin testing and microbial growth monitoring. "The Multiskan Ease was developed to provide the performance researchers need for routine biological analysis in a platform that is easy to adopt, straightforward to operate and designed to support laboratory productivity," said Trent Colville, senior director and general manager of protein detection and quantification at Thermo Fisher Scientific. The system targets academic, biotechnology, pharmaceutical and quality control laboratories.
Thermo Fisher Scientific introduces the Thermo Scientific EMPAD G2 electron detector. Monday 31st August 2026 New detector enables faster 4D STEM imaging, helping researchers uncover material properties with greater speed and detail. Thermo Fisher Scientific has introduced the Thermo Scientific(TM) EMPAD(TM) G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better understand its structure and properties. "The EMPAD G2 gives scientists a deeper view of materials and the information they need to explore what those materials can do," said Glyn Davies, president, materials and structural analysis, Thermo Fisher Scientific. "By making advanced 4D STEM faster, more reliable and easier to use, we can help researchers accelerate discoveries in areas such as semiconductors, energy and advanced materials - and ultimately enable new technologies that can improve our everyday lives." Capturing weaker signals alongside stronger ones can help researchers measure characteristics, including a material's structure, chemistry, strain and electric and magnetic properties in a single experiment. EMPAD G2 supports advanced applications, ranging from strain mapping and differential phase contrast (DPC) to multi-slice electron ptychography for three-dimensional characterization at the atomic scale. As 4D STEM becomes more widely used in academic and industrial research, detector performance is increasingly important. Researchers need to capture large amounts of information quickly while accurately measuring signals that can range from extremely strong to extremely weak. EMPAD G2 is designed specifically to meet these demands and help researchers get reliable quantitative information from a single acquisition. According to David Muller, Ph.D., Samuel B. Eckert Professor of Engineering at the School of Applied and Engineering Physics at Cornell University, this new technology represents an important milestone for scanning transmission electron microscopy. "The EMPAD G2 project gave us a unique opportunity to design a detector specifically optimized for STEM, rather than TEM or x-ray imaging," said Muller. EMPAD G2 is also fully integrated with the user-friendly Thermo Scientific Velox software. Researchers can collect and analyze multiple types of data, including simultaneous 4D STEM and energy-dispersive x-ray spectroscopy (EDS) within a single workflow. This integration helps simplify advanced materials analysis and supports more reliable, repeatable results. SPONSOR MESSAGE ULVAC plasma ashing systems - high-performance solutions for demanding applications. With over 40 years of experience in plasma ashing, ULVAC offers the ENVIRO series for R&D, pilot lines, and high-volume manufacturing. These systems enable efficient photoresist removal with high flexibility and process versatility. System Variants - ENVIRO-1Xa: Single chamber - ENVIRO-1Xa 2C: Dual chamber - ENVIRO-Optima: Triple chamber Plasma Source Overview - ICP (Inductively Coupled Plasma): High-rate removal, reliable, ideal for MEMS and HDIS - MW (Microwave): Low-temperature polymer removal, ~50% less plasma-induced damage - RF Bias: Complements ICP or MW, enables chemical + physical ashing/etching for advanced processes like anisotropic descum or carbonized layer removal ULVAC Europe - Technology Expertise from Munich Established in 1987, ULVAC GmbH in Munich serves the EMEA region. The portfolio includes vacuum and thin film equipment, analytical tools, and vacuum components such as pumps and leak detectors. ULVAC provides solutions for semiconductors, MEMS, and displays - covering sputtering, etching, ion implantation, ashing, and thermal processes - tailored for R&D, pilot lines, and mass production. Driving Innovation Through Vacuum Technology
Brokerages set Thermo Fisher Scientific Inc. (NYSE:TMO) target price at $619.41. Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $619.4091. Financial Markets News A number of research firms have commented on TMO. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price on the stock. Wells Fargo & Company cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. HSBC lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating and lowered their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Barclays lifted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Finally, Jefferies Financial Group restated a "buy" rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Key headlines impacting Thermo Fisher Scientific. Discover more Computer Hardware Financial Markets News Here are the key news stories impacting Thermo Fisher Scientific this week: * Thermo Fisher introduced the Thermo Scientific EMPAD G2 electron detector, designed to enable faster, high-speed four-dimensional scanning transmission electron microscopy. The product could support demand for the company's analytical-instrument portfolio and strengthen its position in advanced materials research. * A recent analysis examines whether Isora could provide Thermo Fisher with an additional long-term growth opportunity, potentially broadening the company's exposure to emerging research and laboratory markets. * Thermo Fisher's latest reported quarter showed solid momentum: adjusted EPS of $6.03 exceeded estimates, revenue reached $11.99 billion, and sales increased 10.5% year over year. Fiscal 2026 EPS guidance remains $24.93-$25.33, but much of this strength may already be reflected in the stock's elevated valuation. * Analyst sentiment remains favorable, with a consensus "Moderate Buy" rating, although the average price target of $619.41 is below recent trading levels. Several firms have raised targets toward $650, suggesting optimism but limited upside at the current valuation. * CEO Marc Casper sold 275 shares for approximately $172,000 after selling 10,000 shares worth about $6.3 million earlier in the month. Both transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as a signal of deteriorating fundamentals, but the sales can still weigh on sentiment. Insider activity. In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders. Discover more Company News Stocks & Bonds Institutional trading of Thermo Fisher Scientific. A number of institutional investors have recently made changes to their positions in the business. VELA Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 15.7% in the second quarter. VELA Investment Management LLC now owns 11,167 shares of the medical research company's stock worth $5,599,000 after acquiring an additional 1,513 shares in the last quarter. HighTower Advisors LLC boosted its stake in Thermo Fisher Scientific by 9.8% in the 2nd quarter. HighTower Advisors LLC now owns 159,181 shares of the medical research company's stock worth $79,807,000 after purchasing an additional 14,180 shares in the last quarter. Advus Financial Partners LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $250,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at approximately $6,969,000. Finally, California State Teachers Retirement System raised its holdings in shares of Thermo Fisher Scientific by 49,331.5% in the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company's stock worth $141,711,778,000 after buying an additional 282,082,924 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock. Thermo Fisher Scientific price performance. Shares of TMO stock opened at $630.66 on Tuesday. The company has a market capitalization of $233.18 billion, a P/E ratio of 33.92, a P/E/G ratio of 2.58 and a beta of 0.85. The company's 50-day simple moving average is $555.52 and its two-hundred day simple moving average is $511.31. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $647.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the firm posted $4.28 earnings per share. The company's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts anticipate that Thermo Fisher Scientific will post 25.12 EPS for the current year. Discover more Stocks & Bonds Thermo Fisher Scientific dividend announcement. The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%. About Thermo Fisher Scientific. Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently. Financial Markets News Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies. Further reading. Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.